New RNA drug aims to reduce blood removal in polycythemia vera patients

NCT ID NCT05499013

Ongoing Disease control Sponsor: Silence Therapeutics plc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called SLN124 in 69 adults with polycythemia vera, a condition where the body makes too many red blood cells. The drug works by blocking a protein that controls iron use, which may lower red blood cell production and reduce the need for regular blood removal (phlebotomy). The trial has two phases: first, an open-label dose-finding part, then a randomized double-blind phase where some patients get the drug and others get a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SLN124 (a small interfering RNA drug that targets a protein involved in iron regulation)
What this could lead to: If it works, this could reduce the need for frequent blood removal (phlebotomy) and help manage polycythemia vera more effectively.
What could go wrong: This is an early-phase trial with only 69 participants, so results may not apply to everyone. The drug may cause side effects or fail to show clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POLYCYTHEMIA VERA

Contacts and locations

Locations

Linear Clinical Research

Nedlands, Australia
Research Site

Hammond, Louisiana, 70403, United States
Research Site

Buffalo, New York, 14203, United States
Research Site

New York, New York, 10029, United States
Research Site

Columbus, Ohio, 43210, United States
Research Site

Huntsville, Texas, 77340, United States
Research Site

Benowa, Australia
Research Site

Hobart, Australia
Research Site

Kurralta Park, Australia
Research Site

Melbourne, Australia
Research Site

Richmond, Australia
Research Site

Plovdiv, Bulgaria
Research Site

Toronto, Canada
Research Site

Freiburg im Breisgau, Germany
Research Site

Hanover, Germany
Research Site

Alessandria, Italy
Research Site

Meldola, Italy
Research Site

Johor Bahru, Malaysia
Research Site

Kuala Terengganu, Malaysia
Research Site

Kuantan, Malaysia
Research Site

Kuching, Malaysia
Research Site

Gdansk, Poland
Research Site

Katowice, Poland
Research Site

Lublin, Poland
Research Site

Barcelona, Spain
Research Site

Madrid, Spain
Research Site 2

Melbourne, Australia
Research Site 2

Plovdiv, Bulgaria

More trials for these conditions

Other studies related to the condition(s) this trial covers.